大型多中心MASH试验筛查队列中磷脂酰乙醇检测潜在MetALD与ALD
本研究基于多中心MASLD药物试验筛查数据库,对2870例有基线PEth数据的患者按饮酒量分层。结果显示11%患者PEth≥20 ng/mL,提示可能需要进一步临床评估以鉴别MetALD或ALD。PEth≥20 ng/mL与GGT升高及HbA1c降低独立相关。
要点
- MASLD试验筛查队列中11%患者PEth≥20 ng/mL,提示潜在酒精摄入被低估。
- PEth≥20 ng/mL与GGT升高(每10 U/L,aOR 1.04)及HbA1c降低(aOR 0.68)独立相关。
- PEth≥100 ng/mL患者中不确定FIB-4评分更常见,需关注纤维化评估准确性。
核心结论
- 在MASLD临床试验筛查队列中,11%患者PEth≥20 ng/mL,提示可能存在需进一步评估的MetALD或ALD。
研究设计与样本
- 多中心数据库回顾性分析,纳入2870例有基线PEth结果的MASLD药物试验筛查患者,按PEth<20、20-<100、≥100 ng/mL分层。
主要发现
- 2560例(89%)PEth低水平,168例(6%)中等水平,142例(5%)高水平,其中92例PEth≥200 ng/mL。
- HbA1c越高与PEth越低相关(P<.001);AST、ALT、GGT在PEth较高患者中升高(均P<.001)。
- PEth≥100 ng/mL患者中不确定FIB-4评分更常见(P<.001)。
- 多变量分析中,PEth≥20 ng/mL与GGT升高(每10 U/L,aOR 1.04,95%CI 1.03-1.06,P<.001)及HbA1c降低(aOR 0.68,95%CI 0.60-0.78,P<.001)相关。
关键数值与推荐
- PEth分层阈值:低<20 ng/mL,中20-<100 ng/mL,高≥100 ng/mL。
- PEth≥20 ng/mL定义为提示需进一步临床评估的酒精摄入水平。
临床怎么用
- 在MASLD临床试验筛查中可系统检测PEth以识别潜在MetALD或ALD,避免仅依赖饮酒问卷。
- 对PEth≥20 ng/mL患者应结合GGT、HbA1c及FIB-4进一步评估酒精摄入与纤维化风险。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Accurate distinction between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlap metabolic and alcohol-associated liver disease (MetALD) is of utmost importance. Due to the potential for underreporting in alcohol use surveys, phosphatidylethanol (PEth) is increasingly utilized in clinical trials to rule out MetALD or ALD. This study examines the prevalence of elevated PEth and its effectiveness in separating phenotypes with dominant MASLD, MetALD, or ALD in the clinical trial setting. METHODS: A multicenter database of patients screened for enrollment in clinical trials for MASLD pharmacologic therapies was reviewed, from which patients with PEth results were identified, then further stratified into low (<20 ng/mL), moderate (20-<100 ng/mL), or high (≥100 ng/mL) alcohol intake groups. RESULTS: Among 2870 patients with baseline PEth data, 2560 (89%) had low, 168 (6%) had moderate, and 142 (5%) had high PEth levels, including 92 with PEth ≥200 ng/mL. Higher hemoglobin A1C was associated with lower PEth (P < .001). Aspartate aminotransferase (P < .001), alanine aminotransferase (P < .001), and γ-glutamyltransferase (P < .001) were elevated in patients with higher PEth results. Indeterminate Fibrosis-4 scores were more prevalent in patients with PEth ≥100 ng/mL (P < .001). In multivariable analysis, PEth ≥20 ng/mL was associated with higher γ-glutamyltransferase (per 10 U/L; adjusted odds ratio, 1.04; 95% confidence interval, 1.03-1.06; P < .001), and lower hemoglobin A1C (adjusted odds ratio, 0.68; 95% confidence interval, 0.60-0.78; P < .001). CONCLUSIONS: In this prospective multicenter cohort of participants screened for MASLD clinical trials with systematically collected PEth, 11% had PEth ≥20 ng/mL, suggesting a level of alcohol consumption that may warrant further clinical evaluation for possible MetALD or ALD.
引用
- Noureddin M, Schattenberg JM, Patil R, et al. Detection of Potential Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction-Associated Steatohepatitis Trial Screening Cohort. Clin Gastroenterol Hepatol. 2026. PMID: 42641902. doi:10.1016/j.cgh.2026.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。